S. Giard

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy for Advanced Breast Cancer: Results of Ganglion Sentinelle et Chimiothérapie Neoadjuvante, a French Prospective Multicentric Study

Jean‐Marc Classe, Virginie Bordes, L. Campion et al. · Journal of Clinical Oncology · 2008 · 264 citations · Full text

Medicine, Oncology, Breast Oncology +16

Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial

Bruno Coudert, Jean‐Yves Pierga, Marie‐Ange Mouret‐Reynier et al. · The Lancet Oncology · 2014 · 142 citations

Medicine, Oncology, Breast Oncology +15

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification

Charlotte K.Y. Ng, Luciano G. Martelotto, Arnaud Gauthier et al. · Genome Biology · 2015 · 136 citations · Full text

Medicine, Genetics, Oncology +16

Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers’ experience

B. Cutuli, C. Cohen-Solal-Le Nir, B. De Lafontan et al. · International Journal of Radiation Oncology*Biology*Physics · 2002 · 127 citations

Medicine, Oncology, Surgery +12

A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis

Claude Nos, S. Giard, H. Mignotte et al. · European Journal of Surgical Oncology · 2008 · 102 citations

Medicine, Oncology, Pathology +17